RAY1225
Phase 3Small molecule
RAY1225 is one of 155 small molecule programs targeting Overweight. It is currently in Phase 3.
6
Indications
11
Total Trials
7
Active Trials
154
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
176 competitors in Obesity
#DrugCompanyPhaseTrials
1Cagrilintide
Novo NordiskPhase 3
Decadron
AAspen Global Incorporated
Phase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Retatrutide
Eli LillyPhase 3
Berobenatide
PfizerPhase 3
RAY1225
GGuangdong Raynovent Biotech Co., Ltd
Phase 3
Naltrexone-Bupropion Combination
CCurrax Pharmaceuticals
Phase 3
PF-08653944
PfizerPhase 3
Ribupatide
KKailera
Phase 3
Survodutide
Boehringer IngelheimPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Function2 trials
Type 2 Diabetes2 trials
4 more indications
Basic Science1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RAY1225. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details